(19)
(11) EP 3 310 760 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.10.2022 Bulletin 2022/42

(45) Mention of the grant of the patent:
14.09.2022 Bulletin 2022/37

(21) Application number: 16734529.7

(22) Date of filing: 21.06.2016
(51) International Patent Classification (IPC): 
C07D 209/94(2006.01)
A61P 37/00(2006.01)
A61P 35/00(2006.01)
A61P 1/00(2006.01)
A61P 3/00(2006.01)
 A61K 31/403(2006.01)
A61P 29/00(2006.01)
A61P 9/00(2006.01)
A61P 7/00(2006.01)
A61P 5/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 209/94; A61P 1/00; A61P 1/04; A61P 1/16; A61P 17/02; A61P 17/06; A61P 17/10; A61P 19/02; A61P 25/00; A61P 29/00; A61P 3/00; A61P 35/00; A61P 37/00; A61P 37/02; A61P 43/00; A61P 5/00; A61P 7/00; A61P 9/00; A61P 3/10; C07C 279/14
(86) International application number:
PCT/US2016/038506
(87) International publication number:
WO 2016/209809 (29.12.2016 Gazette 2016/52)

(54)

CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACETIC ACID FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS

KRISTALLINES L-ARGININSALZ VON (R) -2-(7-(4-CYCLOPENTYL-3-(TRIFLUORMETHYL) BENZYLOXY ) -1,2,3,4-TETRAHYDROCYCLO-PENTA [ B ] INDOL-3-YL) ESSIGSÄURE ZUR VERWENDUNG BEI S1P1-REZEPTOR-ASSOZIERTEN ERKRANKUNGEN

SEL L-ARGININE CRISTALLIN D'ACIDE (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMÉTHYL)BENZYLOXY)-1,2,3,4-TÉTRAHYDROCYCLO-PENTA[B]INDOL-3-YL)ACÉTIQUE POUR UNE UTILISATION DANS DES TROUBLES ASSOCIÉS AU RÉCEPTEUR DE S1P1

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 22.06.2015 US 201562182841 P
20.08.2015 US 201562207531 P

(43) Date of publication of application:
25.04.2018 Bulletin 2018/17

(60) Divisional application:
21178613.2 / 3939965

(73) Proprietor: Arena Pharmaceuticals, Inc.
New York, NY 10017 (US)

(72) Inventors:
  • BLACKBURN, Anthony C.
    San Diego, California 92128 (US)
  • CASTRO, Ryan O.
    San Diego, California 92129 (US)
  • HADD, Mark A.
    San Diego, California 92126 (US)
  • MA, You-An
    Poway, California 92064 (US)
  • MONTALBAN, Antonio Garrido
    San Diego, California 92129 (US)
  • RUETER, Jaimie Karyn
    San Diego, California 92129 (US)
  • SELVEY, Lee Alani
    Poway, California 92064 (US)
  • SHAKYA, Sagar Raj
    San Diego, California 92129 (US)
  • CARLOS, Marlon
    Chula Vista, California 91913 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
WO-A1-2010/011316
 WO-A1-2011/094008
   
  • NORBERT RASENACK ET AL: "Crystal habit and tableting behavior", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 244, no. 1-2, 1 September 2002 (2002-09-01), pages 45-57, XP055291502, NL ISSN: 0378-5173, DOI: 10.1016/S0378-5173(02)00296-X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).